Research in the Field of Drug Design and Development

J 2023

Research in the Field of Drug Design and Development

BIALA, Grazyna, Ewa KEDZIERSKA, Marta KRUK-SLOMKA, Jolanta ORZELSKA-GORKA, Sara HMAIDAN et. al.

Basic information

Original name

Research in the Field of Drug Design and Development

Authors

BIALA, Grazyna (guarantor), Ewa KEDZIERSKA, Marta KRUK-SLOMKA, Jolanta ORZELSKA-GORKA, Sara HMAIDAN, Aleksandra SKROK, Jakub KAMINSKI, Eva HAVRÁNKOVÁ (203 Czech Republic, belonging to the institution), Dominika NADASKA and Ivan MALIK

Edition

Pharmaceuticals, BASEL, MDPI, 2023, 1424-8247

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.600 in 2022

RIV identification code

RIV/00216224:14160/23:00132055

Organization unit

Faculty of Pharmacy

DOI

http://dx.doi.org/10.3390/ph16091283

UT WoS

001074283700001

Keywords in English

drug discovery; drug synthesis; in vivo studies; in vitro studies; clinical trials

Abstract

V originále

The processes used by academic and industrial scientists to discover new drugs have recently experienced a true renaissance, with many new and exciting techniques being developed over the past 5-10 years alone. Drug design and discovery, and the search for new safe and well-tolerated compounds, as well as the ineffectiveness of existing therapies, and society's insufficient knowledge concerning the prophylactics and pharmacotherapy of the most common diseases today, comprise a serious challenge. This can influence not only the quality of human life, but also the health of whole societies, which became evident during the COVID-19 pandemic. In general, the process of drug development consists of three main stages: drug discovery, preclinical development using cell-based and animal models/tests, clinical trials on humans and, finally, forward moving toward the step of obtaining regulatory approval, in order to market the potential drug. In this review, we will attempt to outline the first three most important consecutive phases in drug design and development, based on the experience of three cooperating and complementary academic centers of the Visegrad group; i.e., Medical University of Lublin, Poland, Masaryk University of Brno, Czech Republic, and Comenius University Bratislava, Slovak Republic.

Citovat

BIALA, Grazyna, Ewa KEDZIERSKA, Marta KRUK-SLOMKA, Jolanta ORZELSKA-GORKA, Sara HMAIDAN, Aleksandra SKROK, Jakub KAMINSKI, Eva HAVRÁNKOVÁ, Dominika NADASKA and Ivan MALIK. Research in the Field of Drug Design and Development. Pharmaceuticals. BASEL: MDPI, 2023, vol. 16, No 9, p. 1-23. ISSN 1424-8247. Available from: https://dx.doi.org/10.3390/ph16091283.

@article{2330845,
   author = {Biala, Grazyna and Kedzierska, Ewa and KrukandSlomka, Marta and OrzelskaandGorka, Jolanta and Hmaidan, Sara and Skrok, Aleksandra and Kaminski, Jakub and Havránková, Eva and Nadaska, Dominika and Malik, Ivan},
   article_location = {BASEL},
   article_number = {9},
   doi = {http://dx.doi.org/10.3390/ph16091283},
   keywords = {drug discovery; drug synthesis; in vivo studies; in vitro studies; clinical trials},
   language = {eng},
   issn = {1424-8247},
   journal = {Pharmaceuticals},
   title = {Research in the Field of Drug Design and Development},
   url = {https://www.mdpi.com/1424-8247/16/9/1283},
   volume = {16},
   year = {2023}
}

TY  - JOUR
ID  - 2330845
AU  - Biala, Grazyna - Kedzierska, Ewa - Kruk-Slomka, Marta - Orzelska-Gorka, Jolanta - Hmaidan, Sara - Skrok, Aleksandra - Kaminski, Jakub - Havránková, Eva - Nadaska, Dominika - Malik, Ivan
PY  - 2023
TI  - Research in the Field of Drug Design and Development
JF  - Pharmaceuticals
VL  - 16
IS  - 9
SP  - 1-23
EP  - 1-23
PB  - MDPI
SN  - 14248247
KW  - drug discovery
KW  - drug synthesis
KW  - in vivo studies
KW  - in vitro studies
KW  - clinical trials
UR  - https://www.mdpi.com/1424-8247/16/9/1283
N2  - The processes used by academic and industrial scientists to discover new drugs have recently experienced a true renaissance, with many new and exciting techniques being developed over the past 5-10 years alone. Drug design and discovery, and the search for new safe and well-tolerated compounds, as well as the ineffectiveness of existing therapies, and society's insufficient knowledge concerning the prophylactics and pharmacotherapy of the most common diseases today, comprise a serious challenge. This can influence not only the quality of human life, but also the health of whole societies, which became evident during the COVID-19 pandemic. In general, the process of drug development consists of three main stages: drug discovery, preclinical development using cell-based and animal models/tests, clinical trials on humans and, finally, forward moving toward the step of obtaining regulatory approval, in order to market the potential drug. In this review, we will attempt to outline the first three most important consecutive phases in drug design and development, based on the experience of three cooperating and complementary academic centers of the Visegrad group; i.e., Medical University of Lublin, Poland, Masaryk University of Brno, Czech Republic, and Comenius University Bratislava, Slovak Republic.
ER  -

BIALA, Grazyna, Ewa KEDZIERSKA, Marta KRUK-SLOMKA, Jolanta ORZELSKA-GORKA, Sara HMAIDAN, Aleksandra SKROK, Jakub KAMINSKI, Eva HAVRÁNKOVÁ, Dominika NADASKA and Ivan MALIK. Research in the Field of Drug Design and Development. \textit{Pharmaceuticals}. BASEL: MDPI, 2023, vol.~16, No~9, p.~1-23. ISSN~1424-8247. Available from: https://dx.doi.org/10.3390/ph16091283.

Detailed Information on Publication Record